Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
TGTX
TGTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TGTX News
Soleus Capital Increases Stake in Celcuity
2d ago
Fool
TG Therapeutics Launches NextInMS Platform to Support MS Patients
6d ago
stocktwits
TG Therapeutics Partners with Christina Applegate to Raise MS Awareness
Feb 08 2026
Newsfilter
TG Therapeutics Presents BRIUMVI Data at ACTRIMS Annual Meeting
Feb 06 2026
Newsfilter
Hussman Strategic Advisors Exits Entire Position in TG Therapeutics
Feb 03 2026
Fool
Goldman Sachs Raises TG Therapeutics Price Target to $39, Briumvi Now Available in 16 Countries
Jan 15 2026
stocktwits
S&P 500 Index Falls 0.53% as Tech Stocks Weigh Down Market
Jan 15 2026
NASDAQ.COM
S&P 500, Dow, and Nasdaq Decline Amid Rising Geopolitical Risks
Jan 14 2026
NASDAQ.COM
S&P 500, Dow, and Nasdaq Decline; Nasdaq Hits One-Week Low
Jan 14 2026
NASDAQ.COM
TG Therapeutics (TGTX) Projects $616 Million Revenue in 2025, Exceeding Analyst Estimates
Jan 14 2026
stocktwits
TG Therapeutics Reports $616 Million Revenue for FY 2025, Shares Surge 11.6%
Jan 14 2026
Benzinga
TG Therapeutics Reports $616M Revenue for 2025, Targets Up to $900M in 2026
Jan 14 2026
Benzinga
U.S. Stock Futures Decline as CPI Rises 2.7% Year Over Year
Jan 14 2026
Benzinga
Bank of America Expected to Report $0.96 EPS on $27.87 Billion Revenue
Jan 14 2026
Benzinga
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
Jan 14 2026
NASDAQ.COM
TG Therapeutics Expects Briumvi Revenue of $825M to $850M in FY26
Jan 14 2026
stocktwits
Show More News
